tetano
Editor, Senior Moderator
Clin Infect Dis. 2016 Mar 29. pii: ciw176. [Epub ahead of print]
[h=1]A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-15 season.[/h] Skowronski DM[SUP]1[/SUP], Chambers C[SUP]2[/SUP], Sabaiduc S[SUP]2[/SUP], De Serres G[SUP]3[/SUP], Winter AL[SUP]4[/SUP], Dickinson JA[SUP]5[/SUP], Krajden M[SUP]6[/SUP], Gubbay JB[SUP]7[/SUP], Drews SJ[SUP]8[/SUP], Martineau C[SUP]9[/SUP], Eshaghi A[SUP]4[/SUP], Kwindt TL[SUP]2[/SUP], Bastien N[SUP]10[/SUP], Li Y[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The 2014-15 influenza season was distinguished by an A(H3N2) epidemic of antigenically-drifted virus and vaccine containing identical components to 2013-14. We report 2014-15 vaccine effectiveness (VE) estimates from Canada and explore contributing agent-host factors.
[h=4]METHODS:[/h] VE against medically-attended laboratory-confirmed influenza was derived by test-negative-design. Patients presenting with influenza-like-illness to sentinel outpatient clinics between November 1,2014 and April 30,2015 were eligible to participate. Influenza was diagnosed by RT-PCR. Sanger-sequencing identified amino-acid differences relative to vaccine at key antigenic-sites of the viral hemagglutinin(HA) protein.
[h=4]RESULTS:[/h] Among 1939 eligible participants, 814(42%) tested influenza-positive: 590(72%) influenza/A and 225(28%) influenza/B. Virtually all influenza/A viruses with known subtype (570/577;99%) were A(H3N2) with most sequenced viruses belonging to genetic clades 3C.2a (409/460;89%) or 3C.3b (39/460;9%). Both clades had multiple amino-acid differences from vaccine at antigenic-sites of the HA-protein, but clade-3C.2a viruses bore the pivotal mutations F159Y (cluster-transition-site) and adjacent K160T (predicted gain-of-glycosylation). VE was -16%(95%CI:-49-9%) for A(H3N2) overall: -13%(95%CI:-50-15%) for clade-3C.2a and 52%(95%CI:-16-81%) for clade-3C.3b. Among patients vaccinated in 2014-15 but not 2013-14, VE was 53%(95%CI:10-75%), significantly lower at -32%(95%CI:-75-0%) if also vaccinated in 2013-14 and -54%(95%CI:-109--14%) if serially-vaccinated each year since 2012-13. Among influenza/B detections with known lineage, most (193/199;85%) were B(Yamagata);all were clade-mismatched to vaccine with VE of 42%(95%CI:10-62%). A similar pattern of reduced VE with repeat vaccination was observed for B(Yamagata) but the effect was less pronounced compared to A(H3N2).
[h=4]CONCLUSIONS:[/h] A combination of agent-host factors, including variation in the viral genome and negative effects of repeat vaccination, likely contributed to poor influenza vaccine performance in 2014-15.
? The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
PMID: 27025838 [PubMed - as supplied by publisher]
[h=1]A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-15 season.[/h] Skowronski DM[SUP]1[/SUP], Chambers C[SUP]2[/SUP], Sabaiduc S[SUP]2[/SUP], De Serres G[SUP]3[/SUP], Winter AL[SUP]4[/SUP], Dickinson JA[SUP]5[/SUP], Krajden M[SUP]6[/SUP], Gubbay JB[SUP]7[/SUP], Drews SJ[SUP]8[/SUP], Martineau C[SUP]9[/SUP], Eshaghi A[SUP]4[/SUP], Kwindt TL[SUP]2[/SUP], Bastien N[SUP]10[/SUP], Li Y[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The 2014-15 influenza season was distinguished by an A(H3N2) epidemic of antigenically-drifted virus and vaccine containing identical components to 2013-14. We report 2014-15 vaccine effectiveness (VE) estimates from Canada and explore contributing agent-host factors.
[h=4]METHODS:[/h] VE against medically-attended laboratory-confirmed influenza was derived by test-negative-design. Patients presenting with influenza-like-illness to sentinel outpatient clinics between November 1,2014 and April 30,2015 were eligible to participate. Influenza was diagnosed by RT-PCR. Sanger-sequencing identified amino-acid differences relative to vaccine at key antigenic-sites of the viral hemagglutinin(HA) protein.
[h=4]RESULTS:[/h] Among 1939 eligible participants, 814(42%) tested influenza-positive: 590(72%) influenza/A and 225(28%) influenza/B. Virtually all influenza/A viruses with known subtype (570/577;99%) were A(H3N2) with most sequenced viruses belonging to genetic clades 3C.2a (409/460;89%) or 3C.3b (39/460;9%). Both clades had multiple amino-acid differences from vaccine at antigenic-sites of the HA-protein, but clade-3C.2a viruses bore the pivotal mutations F159Y (cluster-transition-site) and adjacent K160T (predicted gain-of-glycosylation). VE was -16%(95%CI:-49-9%) for A(H3N2) overall: -13%(95%CI:-50-15%) for clade-3C.2a and 52%(95%CI:-16-81%) for clade-3C.3b. Among patients vaccinated in 2014-15 but not 2013-14, VE was 53%(95%CI:10-75%), significantly lower at -32%(95%CI:-75-0%) if also vaccinated in 2013-14 and -54%(95%CI:-109--14%) if serially-vaccinated each year since 2012-13. Among influenza/B detections with known lineage, most (193/199;85%) were B(Yamagata);all were clade-mismatched to vaccine with VE of 42%(95%CI:10-62%). A similar pattern of reduced VE with repeat vaccination was observed for B(Yamagata) but the effect was less pronounced compared to A(H3N2).
[h=4]CONCLUSIONS:[/h] A combination of agent-host factors, including variation in the viral genome and negative effects of repeat vaccination, likely contributed to poor influenza vaccine performance in 2014-15.
? The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
PMID: 27025838 [PubMed - as supplied by publisher]